Immediate test results and patient treatment reduces the likelihood of a readmission “within 30 days of discharge” that could result in hospital penalties under Accountable Care.
“Consolidates and replaces a suitcase full of readers with a single device, that adapts to existing and FDA Cleared Point of Care tests, eliminates transportation of patient samples to central labs by testing the patient wherever they are, and transmits test results directly to The Cloud. The device that finally makes Point of Care diagnostics practical for healthcare providers."
We are so excited to be a part of an exclusive group of companies who have been named a COOL Company for the 2nd consecutive year. The COOL Companies list identifies San Diego’s fastest growing and most exciting companies; put together by Connect, which pairs tech and life science companies with quality capital and mentorship. […]
We are pleased to announce that SimpleTest™ by iAssay has over 100 investors. This is an incredible achievement for us as a company and we want to thank everyone who believes in our mission. It is thanks to you that we will be able to revolutionize the healthcare industry and help millions of people to […]
Innovative Program Aims to Improve Medical Testing Capabilities San Diego, CA 04/29/2021- iAssay announced this week that they have been awarded a Phase 1 SBIR (Small Business Innovation Research) Award through AFWERX. iAssay makes a patent-protected medical device called SimpleTest™ that can interpret test results and transmit preserved imaging and quantitative results electronically from point of […]
Thanks to you, our amazing investors and supporters, we’ve completed our first WeFunder milestone, closing the early bird $200,000 investment stage on Wefunder.com/iAssay.We want to thank this entire amazing community for helping us reach this goal and for believing in what we are committed to do.We have exciting client announcements and major partnerships coming down […]
Meet Paul F. Rashid, MD, our new Advisory Board Member and investor. We are so fortunate to have him aboard! iAssay has an EarlyBird investment special for a short time. Visit the site for more details: www.WeFunder.com/iAssay
For Release March 8, 2021 iAssay and DDTD Tag Team Against COVID-19 San Diego— March 8, 2021 — iAssay, Inc., and DDTD (Drugs & Diagnostics for Tropical Diseases), a 501(c)(3) nonprofit, have signed a Memorandum of Understanding (MOU). DDTD is a mission-driven organization to develop accurate, affordable, mass-market treatments and diagnostics for low-resourced and under-served […]
We are pleased to share a recording of iAssay’s recent webinar. In this video iAssay’s Founder and CEO, Lonnie Adelman presents an overview of the medical testing industry and explains the trend to point of care testing. He then discusses the company’s breakthrough point of care product, SimpleTest™, and how this device is positioned to […]
Hello, I am reaching out to our investors and future investors to invite you to a Zoom Webinar to share more details about our new and exciting SimpleTest™ product ( www.WeFunder.com/iAssay ) that is completely revolutionizing the medical testing industry. Here are the details for the Webinar: When: Mar 2, 2021 12:00 PM Eastern Time […]
Dear investors, I am pleased to share some exciting news with you…We are no longer pre-revenue! GattaCo, makers of next generation medical diagnostics and simplified sample collection and processing, has signed a Memorandum of Understanding (MOU) with iAssay enabling engineers and scientists to work together to integrate and optimize their products to provide accurate, enhanced […]